The first genome-wide association study in the Argentinian and Chilean populations identifies shared genetics with Europeans in Alzheimer's disease
- PMID: 37985413
- PMCID: PMC10917041
- DOI: 10.1002/alz.13522
The first genome-wide association study in the Argentinian and Chilean populations identifies shared genetics with Europeans in Alzheimer's disease
Abstract
Introduction: Genome-wide association studies (GWAS) are fundamental for identifying loci associated with diseases. However, they require replication in other ethnicities.
Methods: We performed GWAS on sporadic Alzheimer's disease (AD) including 539 patients and 854 controls from Argentina and Chile. We combined our results with those from the European Alzheimer and Dementia Biobank (EADB) in a meta-analysis and tested their genetic risk score (GRS) performance in this admixed population.
Results: We detected apolipoprotein E ε4 as the single genome-wide significant signal (odds ratio = 2.93 [2.37-3.63], P = 2.6 × 10-23 ). The meta-analysis with EADB summary statistics revealed four new loci reaching GWAS significance. Functional annotations of these loci implicated endosome/lysosomal function. Finally, the AD-GRS presented a similar performance in these populations, despite the score diminished when the Native American ancestry rose.
Discussion: We report the first GWAS on AD in a population from South America. It shows shared genetics modulating AD risk between the European and these admixed populations.
Highlights: This is the first genome-wide association study on Alzheimer's disease (AD) in a population sample from Argentina and Chile. Trans-ethnic meta-analysis reveals four new loci involving lysosomal function in AD. This is the first independent replication for TREM2L, IGH-gene-cluster, and ADAM17 loci. A genetic risk score (GRS) developed in Europeans performed well in this population. The higher the Native American ancestry the lower the GRS values.
Keywords: Hispanic; Latin America; Native-American ancestry; South America; admixture; genetic risk score; genetics; genome-wide association study.
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or potential conflict of interest. Author disclosures are available in the supporting information
Figures


References
Publication types
MeSH terms
Substances
Grants and funding
- FI20/00215/Instituto de Salud Carlos III
- CONICET
- PUE060/Agencia Nacional de Promoción Científica y Tecnológica
- PICTO-2021-UCTH00005/Agencia Nacional de Promoción Científica y Tecnológica
- PICTO-2021-UCTH00006/Agencia Nacional de Promoción Científica y Tecnológica
- PID-2011-0059/Agencia Nacional de Promoción Científica y Tecnológica
- PIBT/09-2013/Agencia Nacional de Promoción Científica y Tecnológica
- PICT-2016-4647/Agencia Nacional de Promoción Científica y Tecnológica
- PICT2019-0656/Agencia Nacional de Promoción Científica y Tecnológica
- 115975/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- 115985/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- PI13/02434/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- PI16/01861/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- PI17/01474/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- PI19/01240/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- PI19/01301/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- PI22/01403/European Union / EFPIA Innovative Medicines Initiative joint undertaking ADAPTED and MOPEAD
- ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-"Una manera de hacer Europa"
- AC19/00097/JPco-fuND-2 "Multinational research projects on Personalized Medicine for Neurodegenerative Diseases,"
- AC17/00100/European Innovative Research & Technological Development Projects in Nanomedicine
- ID15150012/ANID/FONDAP
- Alexander von Humboldt Foundation
- International Society for Neurochemistry
- 1130947/Chilean National Fund for Science and Technology (FONDECYT)
- BMBF: 01ED1619A/German Federal Ministry of Education and Research
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous